http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Yee Zee Bae (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
Yee Zee Bae,Jae Hyuk Jung,Chang Hoon Moon,Seong Hyun Kim,Hyuk Chan Kwon,Jae Seok Kim,Hyo Jin Kim 대한암학회 2002 Cancer Research and Treatment Vol.34 No.3
Purpose: There are few therapeutic options in patientswith colorectal cancer that have progressed or recurredfollowing 5-fluorouracil (5-FU) based therapy. We evaluatedthe efficacy and toxicity of oxaliplatin, 5-FU, leucovorin(Mayo clinic regimen) in 5-FU pretreated advancedcolorectal cancer patients.Materials and Methods: Twenty-eight patients wereenrolled in this study between January 1999 and May2001. Patients were treated with oxaliplatin 150 mg/m2 onday 1 as a 2-hr infusion and 5-FU 425 mg/m2, leucovorin20 mg/m2, bolus for 5 days. Treatment courses wererepeated in 4-week intervals.Results: The objective response rate was 25% for 28assessable patients, all cases registered a partial response.Eleven patients (39%) demonstrated stable disease,and ten (36%) progressed. The median responseduration was 5.5 months, and the median time to progressionwas 6.3 months. The median overall survivaltime was 13.5 months from the start of the chemotherapy.From the 120 cycles analyzed, grade 3,4 hematologictoxicities included neutropenia: 1.6%, and thrombocytopenia:1.6%. The frequent grade 3.4 non-hematologicadverse reactions were nausea/vomiting (25.0%), diarrhea(14.3%), stomititis (3.6%), and neuropathy (3.6%). Therewere no treatment-related deaths.Conclusion: This phase II study had relatively highertoxicity than previous studies, and did not show anincreased significant response rate. These high levels oftoxicity suggest that the study treatment combination ofoxaliplatin with a full dose Mayo clinic regimen arm is nofeasible. Therefore, this regimen will be discontinued anda safer regimen will be adopted. (Cancer Res Treat. 2002;34:218-222)
-
Je Hyuk Chung,Yee Zee Bae,Sung Hyun Kim,Chang Hoon Moon,Jun Young Chung,Hyuk Chan Kwon,Jae Seok Kim,Hyo Jin Kim 대한암학회 2002 Cancer Research and Treatment Vol.34 No.5
Purpose: There is no effective treatment for patientswith advanced gastric cancer having failed to respond tofirst line chemotherapy. The aim of this study was toevaluate the therapeutic activity, and safety, of a FEPregimen in patients with a recurrence of, or metastatic,gastric cancer that had been unresponsive to primarychemotherapy.Materials and Methods: Recurred or metastatic gastriccancer patients that did not respond to a 5-fluorouracilbased regimen were entered into this trial. The patientswere treated with FEP (5-FU, etoposide and cisplatin) assalvage chemotherapy. The treatment regimen was 5-FU(900 mg/m2/day) by continuous infusion for 3 days, etoposide(90 mg/m2/day) on days 1, 2 and 3, and cisplatin(60 mg/m2/day) on day 2. This treatment was repeatedevery 3 weeks.Results: Between December 1997 and October 2001, 28patients were enrolled to the study. The response rate was32.1% (95% CI 15.5~57.8%). The median times to progressionand survival duration were 23~33 weeks, respectively.Among a total of 187 cycles of chemotherapy, the grade3 and 4 hematological toxicities were leukopenia (6.4%),thrombocytopenia (1.6%), and grade 3 non-hematologicalside effects of nausea/vomiting (17.9%).Conclusion: FEP combination chemotherapy seems tobe an effective treatment regimen for gastric cancer assalvage chemotherapy. To confirm these results, largescale of clinical trials will be required. (Cancer Res Treat. 2002;34:382-387)
-
급성 대장 가성 폐쇄증에서 Neostigmine의 치험
김완수 ( Wan Su Kim ),한상영 ( Sang Young Han ),배이지 ( Yee Zee Bae ),장진석 ( Jin Seok Jang ),정제혁 ( Je Hyuk Chung ),이종훈 ( Jong Hoon Lee ),노명환 ( Myung Hwan Roh ),최석렬 ( Seok Ryeol Choi ),신우원 ( Woo Won Shin ) 대한소화기학회 2003 대한소화기학회지 Vol.41 No.1
Acute colonic pseudo-obstruction (ACPO) known as Ogilvie`s syndrome is characterized by massive dilatation of the colon without a mechanical obstruction with unclear pathophysiology. The ACPO is associated with wide variety of medical and surgical conditions, especially pregnancy, cesarean section, and trauma. Usually, the conservative therapy of 2-3 days is enough for its treatment. However, if it shows no effect, colonoscopic decompression is recommended. As an alternative, neostigmine has been reported to be effective in the treatment of ACPO. Here, we report a case of idiopathic ACPO treated with neostigmine. The initial treatment was conservative but showed no effect, and thus colonoscopic decompression was followed. After decompression, symptoms improved. However, 10 days after decompression, abdominal distension recurred. Thus, we injected 2.0 mg of neostigmine intravenously for 3 minutes. It improved the symptom. Seven days later, the symptoms were aggravated, so 1.0 mg of neostigmine was administrated twice, which did not work. The patient was transferred for exploration, and a total colectomy was carried out. Seven days after colectomy, the patient died of sepsis. (Korean J Gastroenterol 2003;41:64-69)
-
김경태 ( Kyoung Tae Kim ),백정환 ( Jeung Hoan Paik ),이창재 ( Chang Jae Lee ),김진호 ( Jin Ho Kim ),배이지 ( Yee Zee Bae ),서봉근 ( Bong Gun Seo ),권혁찬 ( Hyuk Chan Kwon ),오성용 ( Sung Yong Oh ),김성현 ( Sung Hyun Kim ),김재석 ( 대한내과학회 2005 대한내과학회지 Vol.69 No.3
목적: 다발성골수종은 단일 클론에서 유래하는 B 림프구의 악성종양으로 형질세포의 악성증식을 특징으로 하는 질환이다. 다발성 골수종은 임상 양상이 매우 다양하게 나타나며 생존율은 수개월에서 10년 이상으로 다양하다. 이 연구의 목적은 다발성골수종에서 특정한 세포유전학적 염색체 결함이 예후인자로서 가치가 있는지 알아보고자 하였다. 방법: 1995년 4월부터 2004년 8월까지 다발성골수종으로 진단 받은 환자 40예를 대상으로 하였다. 세포유전학적 검사는 세포중기 핵형분석을 하여 염색체 검사를 시행하였다. 정상염색체를 보인 군(A군)과 13번 염색체 결손 또는 부분 결손이나 저두배수체를 보이는 군(B군), 그리고 그 외의 염색체 이상을 보이는 군(C군)으로 분류하였다. 결과: 관찰기간의 중앙값은 13.1개월이었다(범위 1.5~92.1개월). 항암화학요법에 대한 총 반응율은 58.8%였고, A군, B군, C군 간의 치료에 대한 반응율은 각각 56.3%, 33.3%, 75%였다(p=0.229). 생존기간에 영향을 미치는 예후인자로는 임상적 병기, 활동도, 혈청 크레아티닌 수치, 성별 그리고 염색체 이상 여부 등이었다. A군, B군, C군 사이에 중앙생존기간이 유의하게 차이가 있었으며(각각 34.9개월, 8.5개월, 19.8개월, p=0.0125), 염색체 이상 중 13번 염색체 결손 또는 부분 결손과 염색체 저두배수체성이 다발성골수종에서 생존기간에 불리하게 작용하였다. 결론: 다발성 골수종에서 진단시 염색체 이상은 임상적 예후에 중요한 인자로 작용한다. Background: Multiple myeloma is a clonal B-cell malignancy manifested by the accumulation of terminally differentiated plasma cells. The disease is characterized by clinical heterogeneity, with survival ranging from a few months to more than 10 years. The purpose of this study is to evaluate the prognostic value of specific chromosomal abnormality in multiple myeloma. Methods: We analyzed the clinical records of 40 patients who were diagnosed as multiple myeloma, between April, 1995 and August, 2004. Cytogenetic analysis was conducted by metaphase karyotype analysis. Patients were grouped into normal cytogenetic group (arm A), complete or partial deletion of chromosome 13 and hypodiploidy group (arm B) and other cytogenetic abnormality group (arm C). Results: Median follow up duration was 13.1 months (range 1.5-92.1). Overall response rate to chemotherapy was 58.8% and response rate among arm A, B and C were 56.3%, 33.3% and 75%, respectively (p=0.229). The prognostic factors affecting survival were clinical stage, performance status, serum creatinine level, sex and chromosomal abnormality. The median overall survival was significantly different among arm A, B and C (34.9 months, 8.5 months and 19.8 months, respectively, p=0.0125). Conclusion: chromosomal abnormality, especially, complete or partial deletion of chromosome 13 and hypodiploidy at initial diagnosis is significantly associated with survival duration. (Korean J Med 69:303-311, 2005)
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
